7,571.63

-8.44

-0.11%

52,111.94

+341.63

+0.66%

25,322.99

-114.01

-0.45%

2,817.68

+5.83

+0.21%

4.8900

-0.0390

-0.79%

20.76

+1.34

+6.91%

3,958.10

+59.20

+1.52%

76,766.40

-918.95

-1.18%

Crude Oil Dec 26

96.54

-7.58

-7.28%

US Private Equity

10,850.63

-82.20

-0.75%

Frankfurt - Delayed Quote EUR

Zevra Therapeutics, Inc. (1GDA.F)

9.18 +0.10 (+1.10%)

As of 3:42:59 PM GMT+1. Market Open.

Zevra Therapeutics Announces Details for Q3 2026 Financial Results Call

GlobeNewswire 13d ago

ZVRA
Zevra Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire 1mo ago

ZVRA
Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium

GlobeNewswire 2mo ago

ZVRA
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 2mo ago

ZVRA
What Could Zevra Therapeutics (ZVRA) New NPC Data Mean For Its Europe Review?

Simply Wall St. 2mo ago

ZVRA
Zevra Therapeutics Q2 Earnings Call Highlights

MarketBeat 2mo ago

ZVRA
Zevra Therapeutics Inc (ZVRA) (Q2 2026) Earnings Call Highlights: Revenue Surges 53% as ...

GuruFocus.com 2mo ago

ZVRA
Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates

Zacks 2mo ago

ZVRA
Zevra Reports Second Quarter 2026 Financial Results and Corporate Update

GlobeNewswire 2mo ago

ZVRA
Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference

GlobeNewswire 2mo ago

ZVRA
Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC)

GlobeNewswire 2mo ago

ZVRA
ZVRA Stock Sinks 23% On EU Setback — Analyst Says Risk Is ‘A Headwind, But Not Insurmountable’

Stocktwits 3mo ago

ZVRA

Mobilize your Website

View Site in Mobile | Classic

Share by: